CLN Stock Overview
An integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CLN from our risk checks.
Celon Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł15.56 |
| 52 Week High | zł17.94 |
| 52 Week Low | zł14.00 |
| Beta | 0.83 |
| 1 Month Change | -3.47% |
| 3 Month Change | -0.51% |
| 1 Year Change | -2.14% |
| 3 Year Change | -66.10% |
| 5 Year Change | -65.99% |
| Change since IPO | -30.16% |
Recent News & Updates
Recent updates
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24
Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Shareholder Returns
| CLN | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 0.4% | -0.1% | -2.3% |
| 1Y | -2.1% | -10.9% | 18.8% |
Return vs Industry: CLN exceeded the Polish Pharmaceuticals industry which returned -10.9% over the past year.
Return vs Market: CLN underperformed the Polish Market which returned 18.8% over the past year.
Price Volatility
| CLN volatility | |
|---|---|
| CLN Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 8.9% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: CLN has not had significant price volatility in the past 3 months.
Volatility Over Time: CLN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 568 | Maciej Wieczorek | www.celonpharma.com |
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland.
Celon Pharma S.A. Fundamentals Summary
| CLN fundamental statistics | |
|---|---|
| Market cap | zł794.44m |
| Earnings (TTM) | -zł34.32m |
| Revenue (TTM) | zł209.15m |
3.8x
P/S Ratio-23.1x
P/E RatioIs CLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLN income statement (TTM) | |
|---|---|
| Revenue | zł209.15m |
| Cost of Revenue | zł63.59m |
| Gross Profit | zł145.56m |
| Other Expenses | zł179.88m |
| Earnings | -zł34.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 18, 2024
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 69.60% |
| Net Profit Margin | -16.41% |
| Debt/Equity Ratio | 2.9% |
How did CLN perform over the long term?
See historical performance and comparison